2 result(s) displayed (1 - 2 of 2):

VaxGen to liquidate, merge or sell (from Corporate Dealmaker)

Murphy's law has been enveloping VaxGen Inc. Its latest negative came Friday, after the cash-strapped biopharmaceutical company had to terminate a deal, reporting strong shareholder opposition to a proposed merger with privately held...

Posted on March 31, 2008 2:05 PM

Tech Transfer: From bioscience to defense (from Corporate Dealmaker)

U.S. Genomics hopes to adapt its analyzer technology to detect bioterror threats, like the anthrax sent through U.S. mail.

Posted on August 15, 2006 11:31 AM